Optruma (Raloxifene Hydrochloride)

Raloxifene Hydrochloride, the active ingredient in Optruma, is a selective estrogen receptor modulator presented as an oral tablet for oral use. It is indicated for the prevention and treatment of postmenopausal osteoporosis and for reducing the risk of invasive breast cancer in high‑risk postmenopausal women.

GNH USA supplies Optruma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, oncology centres and clinics worldwide. Our quality‑assured manufacturing follows EU GMP standards, ensuring consistent potency and safety for patients across global markets.

Raloxifene acts on the estrogen receptor pathway to improve bone density and modulate breast tissue risk.

- Postmenopausal osteoporosis: increases bone mineral density and reduces bone resorption, helping prevent fractures. - High‑risk postmenopausal women: lowers the incidence of invasive breast cancer. - Osteopenia: improves bone mineral density to delay progression to osteoporosis.

Raloxifene may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: transient warmth and sweating. - Leg cramps: muscle tightness, often nocturnal. - Peripheral edema: swelling of ankles or feet. - Nausea: mild gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Deep vein thrombosis: clot formation in deep veins. - Pulmonary embolism: blockage of pulmonary arteries. - Stroke: cerebrovascular accident. - Myocardial infarction: heart attack. - Severe allergic reaction (anaphylaxis): rapid onset of hives, swelling, breathing difficulty. - Liver function abnormalities: elevated transaminases.

Before prescribing raloxifene, clinicians should consider several safety measures.

- Assess bone mineral density before initiating therapy: baseline DEXA scan recommended. - Evaluate personal or family history of thromboembolic events: consider alternative therapy if high risk. - Monitor lipid profile and cardiovascular status: raloxifene may affect cholesterol levels. - Avoid use in patients with active liver disease: hepatic impairment can increase exposure. - Counsel about potential hot flashes and leg cramps: manage symptomatically. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture.

Raloxifene can interact with other medicines, requiring careful review.

Major Interactions (Avoid): - Combined estrogen therapy: increases risk of thromboembolism. - Warfarin: may potentiate anticoagulant effect, raising bleeding risk. - Tamoxifen: antagonistic effect on breast tissue may reduce efficacy.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise raloxifene plasma levels. - CYP3A4 inducers (e.g., rifampin): may lower raloxifene exposure. - Diuretics: may exacerbate electrolyte disturbances.